Photodynamic therapy using 5-aminolaevulinic acid for the treatment of dysplasia in Barrett's oesophagus

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 5, 2008, Pages 851-858

  Dunn, Jason ^a   Lovat, Laurence ^a  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

5 Aminolaevulinic acid; Barrett's oesophagus; Dysplasia; Mucosal ablation; Photodynamic therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; ANTIEMETIC AGENT; ASPARTATE AMINOTRANSFERASE; OMEPRAZOLE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PLACEBO; PROTON PUMP INHIBITOR; PROTOPORPHYRIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BARRETT ESOPHAGUS; BLADDER CANCER; CANCER RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG TUMOR LEVEL; DYSPLASIA; EARLY CANCER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS PERFORATION; ESOPHAGUS RESECTION; ESOPHAGUS STRICTURE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEME SYNTHESIS; HUMAN; HYDRATION; HYPERVOLEMIA; HYPOTENSION; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORTALITY; NAUSEA; NEUROPATHY; NONHUMAN; ODYNOPHAGIA; OPTIMAL DRUG DOSE; PATIENT SAFETY; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PORPHYRIA; PRECANCER; RADIOFREQUENCY ABLATION; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SYSTEMATIC REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VOMITING; ANIMAL; CONTROLLED CLINICAL TRIAL; DRUG SCREENING; ESOPHAGUS TUMOR; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHOTOCHEMOTHERAPY; REVIEW;

ADMINISTRATION, ORAL; AMINOLEVULINIC ACID; ANIMALS; BARRETT ESOPHAGUS; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; ESOPHAGEAL NEOPLASMS; HUMANS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 41949092403     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.5.851     Document Type: Article

References (42)

1. Marcus SL, Sobel RS, Golub AL, et al. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. J Clin Laser Med Surg 1996;14:59-66
2. Poh-Fitzpatrick MB. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatology 1986;3:148-57
3. Lofgren LA, Ronn AM, Nouri M, et al. Efficacy of intravenous delta-aminolaevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 1995;72:857-64
4. Barr H, Shepherd NA, Dix A, et al. Eradication of high-grade dysplasia in columnar-lined (Barrett's) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet 1996;348:584-5
5. Phillips RW, Wong RK. Barrett's esophagus: natural history, incidence, etiology, and complications. Gastroenterol Clin North Am 1991;20:791-816
6. Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology 1993;105:40-50
7. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76
8. Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole. Gastrointest Endosc 2000;51:659-63
9. Kelty CJ, Ackroyd R, Brown NJ, et al. Endoscopic ablation of Barrett's oesophagus: a randomized-controlled trial of photodynamic therapy vs. argon plasma coagulation. Aliment Pharmacol Ther 2004;20:1289-96
10. Sampliner RE, Faigel D, Fennerty MB, et al. Effective and safe endoscopic reversal of nondysplastic Barrett's esophagus with thermal electrocoagulation combined with high-dose acid inhibition: a multicenter study. Gastrointest Endosc 2001;53:554-8
11. Dulai GS, Jensen DM, Cortina G, et al. Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett's esophagus. Gastrointest Endosc 2005;61:232-40
12. Sharma VK, Wang KK, Overholt BF, et al. Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc 2007;65:185-95
13. Barr H, Tralau CJ, Macrobert AJ, et al. Photodynamic therapy in the normal rat colon with phthalocyanine sensitisation. Br J Cancer 1987;56:111-8
14. Overholt BF, Panjehpour M, Haydek JM. Photodynamic therapy for Barrett's esophagus: follow-up in 100 patients. Gastrointest Endosc 1999;49:1-7
15. Overholt BF, Wang KK, Burdick JS, et al. Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc 2007;66:460-8
16. Hemminger LL, Wolfsen HC. Photodynamic therapy for Barrett's esophagus and high grade dysplasia: results of a patient satisfaction survey. Gastroenterol Nurs 2002;25:139-41
17. Overholt BF, Panjehpour M, Halberg DL. Photodynamic therapy for Barrett's esophagus with dysplasia and/or early stage carcinoma: long-term results. Gastrointest Endosc 2003;58:183-8
18. Regula J, Macrobert AJ, Gorchein A, et al. Photosensitisation and photodynamic therapy of oesophageal, duodenal, and colorectal tumours using 5 aminolaevulinic acid induced protoporphyrin IX: a pilot study. Gut 1995;36:67-75
19. Arnold DW, Kennedy GL, Keplinger ML, Calandra JC. Mutagenicity studies with delta-aminolevulinic-acid. Food Cosmetics Toxicol 1975;13:63-8
20. Kennedy GL, Arnold DW, Calandra JC. Toxicity studies with delta-aminolevulinic-acid. Food Cosmetics Toxicol 1976;14:45-7
21. Meyer J, Meyer MC, Golub AL. Pharmacokinetics of aminolevulinic acid after oral and intravenous administration in dogs. Drug Metab Dispos 1999;27:432-5
22. Dalton JT, Yates CR, Yin D, et al. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther 2002;301:507-12
23. Webber J, Kessel D, Fromm D. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol 1997;37:151-3
24. Berlin NI, Neuberger A, Scott JJ. Metabolism of delta-aminolaevulic acid. 1. Normal pathways, studied with the aid of N-15. Biochem J 1956;64:80-90
25. Berlin NI, Neuberger A, Scott JJ. Metabolism of delta-aminolaevulic acid. 2. Normal pathways, studied with the aid of C-14. Biochem J 1956;64:90-100
26. Kennedy JC, Pottier RH. Endogenous protoporphyrin-IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol 1992;14:275-92
27. Gossner L, Stolte M, Sroka R, et al. Photodynamic ablation of high-grade dysplasia and early cancer in Barrett's esophagus by means of 5-aminolevulinic acid. Gastroenterology 1998;114:448-55
28. Ackroyd R, Brown NJ, Davis MF, et al. Photodynamic therapy for dysplastic Barrett's oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut 2000;47:612-7
29. Kelty CJ, Ackroyd R, Brown NJ, et al. Comparison of high- vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barrett's esophagus. Surg Endosc 2004;18:452-8
30. Mackenzie GD, Jamieson NF, Novelli MR, et al. How light dosimetry influences the efficacy of photodynamic therapy with 5-aminolaevulinic acid for ablation of high-grade dysplasia in Barrett's esophagus. Lasers Med Sci 2007 [Epub ahead of print]
31. Mackenzie G, Selvasekar C, Jamieson N, et al. Low incidence of esophageal adenocarcinoma following optimal regimen of ALA PDT for high grade dysplasia in Barrett's esophagus. Gastrointest Endosc 2007;65:AB132
32. Pech O, Gossner L, May A, et al. Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia. Gastrointest Endosc 2005;62:24-30
33. Sylantiev C, Schoenfeld N, Mamet R, et al. Acute neuropathy mimicking porphyria induced by aminolevulinic acid during photodynamic therapy. Muscle Nerve 2005;31:390-3
34. Forcione DG, Hasan T, Ortel BJ, Nishioka NS. Optimization of aminolevulinic acid-based photodynamic therapy of Barrett's esophagus with high grade dysplasia. Gastrointest Endosc 2004;59:251
35. Haringsma J, Siersema PD, Kuipers EJ. Endoscopic ablation of Barrett's neoplasia: Rotterdam results. Gastrointest Endosc 2004;59:A252
36. Ban S, Mino M, Nishioka NS, et al. Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett's esophagus. Am J Surg Pathol 2004;28:1466-73
37. Overholt BF, Lightdale CJ, Wang KK, et al. Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc 2005;62:488-98
38. Shand A, Dallal H, Palmer K, et al. Adenocarcinoma arising in columnar lined oesophagus following treatment with argon plasma coagulation. Gut 2001;48:580-1
39. Van Laethem JL, Peny MO, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus. Gut 2000;46:574-7
40. Hornick JL, Blount PL, Sanchez CA, et al. Biologic properties of columnar epithelium underneath reepithelialized squamous mucosa in Barrett's esophagus. Am J Surg Pathol 2005;29:372-80
41. Grossman HB, Gomella L, Fradet Y, et al. A phase III, multicenter comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of superficial papillary lesions in patients with bladder cancer. J Urol 2007;178:62-7
42. Collaud S, Warloe T, Jordan O, et al. Clinical evaluation of bioadhesive hydrogels for topical delivery of hexylaminolevulinate to Barrett's esophagus. J Control Rel 2007;123:203-10